CN105688088A - 一种用于治疗更年期抑郁症综合征的药物制剂 - Google Patents
一种用于治疗更年期抑郁症综合征的药物制剂 Download PDFInfo
- Publication number
- CN105688088A CN105688088A CN201610203268.4A CN201610203268A CN105688088A CN 105688088 A CN105688088 A CN 105688088A CN 201610203268 A CN201610203268 A CN 201610203268A CN 105688088 A CN105688088 A CN 105688088A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- radix
- pharmaceutical preparation
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 29
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 45
- 239000002775 capsule Substances 0.000 claims abstract description 40
- 239000008589 Cortex Fraxini Substances 0.000 claims abstract description 16
- 239000009636 Huang Qi Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 3
- 235000011477 liquorice Nutrition 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 25
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 15
- 241000600550 Lagotis brevituba Species 0.000 claims description 15
- 241000984131 Lagotis clarkei Species 0.000 claims description 15
- 229940097275 indigo Drugs 0.000 claims description 15
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 208000024714 major depressive disease Diseases 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- -1 tincture Substances 0.000 claims description 2
- 229940098465 tincture Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 10
- 239000000463 material Substances 0.000 abstract description 3
- 231100000820 toxicity test Toxicity 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 241001671653 Aconitum carmichaelii Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000931705 Cicada Species 0.000 abstract 1
- 244000062241 Kaempferia galanga Species 0.000 abstract 1
- 235000013421 Kaempferia galanga Nutrition 0.000 abstract 1
- 241000382298 Lagotis Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241001531051 Potentilla chinensis Species 0.000 abstract 1
- 240000006021 Solidago canadensis Species 0.000 abstract 1
- 235000003657 Solidago canadensis Nutrition 0.000 abstract 1
- 244000038231 Strobilanthes dyerianus Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 241001521901 Tribulus lanuginosus Species 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 10
- 229920001353 Dextrin Polymers 0.000 description 8
- 239000004375 Dextrin Substances 0.000 description 8
- 235000019425 dextrin Nutrition 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 229960004793 sucrose Drugs 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 206010003439 Artificial menopause Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241001529793 Dipsas Species 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008642 heat stress Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000009541 kuntai capsule Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229950007863 nilestriol Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗更年期抑郁症综合征的药物制剂及其用途,药物制剂含有:当归、郁金、佩兰、蝉蜕、黄芪、甘草、连翘、炮附片、刺五加、委陵菜、泽兰、青风藤、一枝黄花、洪连、草豆蔻、秦皮、狗脊、蒲公英、乌梅、桑葚、浮小麦、松花粉、蒺藜苗、败酱草、红背马蓝。本发明选用的中药材,注重阴阳协调,利用各味药的综合作用治疗更年期综合征,经过毒性试验可以说明本发明的安全性较高,适合进一步推广应用。从中药材中提取的蛋白质等物质,容易被人体利用,达到解郁散结、安神定气具有良好的作用。另外,本发明的胶囊剂操作简单适合工艺化大生产。
Description
技术领域
本发明属于中药技术领域,尤其是涉及一种用于治疗更年期抑郁症综合征的药物制剂及其用途。
背景技术
更年期抑郁症综合征是当今社会不断提起的字眼,社会的高速发展给许多人带来压力,而压力得不到释放最终导致抑郁症等净胜疾病的产生,抑郁症是情感性精神障碍的一种情感状态,情感性精神障碍是指以心境显著而持久的改变(高涨或低落)为基本临床表现,并伴有相应思维和行为异常的一类精神障碍。
更年期综合征又称更年期综合征,指妇女绝经前后出现性激素波动或减少所致的一系列以自主神经系统功能紊乱为主,伴有神经心理症状的一组症候群。绝经可分为自然绝经和人工绝经两种。自然绝经指卵巢内卵泡用尽,或剩余的卵泡对促性腺激素丧失了反应,卵泡不再发育和分泌雌激素,不能刺激子宫内膜生长,导致绝经。人工绝经是指手术切除双侧卵巢或用其他方法停止卵巢功能,如放射治疗和化疗等。单独切除子宫而保留一侧或双侧卵巢者,不作为人工绝经。
更年期综合征的诊断原则:①年龄45~55岁的妇女,伴有上述临床表现的症状;②内分泌测定:雌二醇水平降低,促卵泡生成激素升高,促黄体生成激素增多;③应排除精神、神经性疾病,甲状腺机能亢进,心血管疾病等。
随着现今生活节奏的明显加快、工作压力的显著增加,更年期妇女症状愈加明显,其临床表现也越复杂,有的单见一种症状,有的多种表现共存,少数病人还有可能出现个性特征改变,其症状持续时间也有长有短,短则数月半载,长则可达数年之久,使其既背负着沉重的精神压力,又影响了家庭生活的和谐。大多数妇女能够通过神经内分泌的自我调节达到新的平衡而无自觉症状,但亦有部分妇女症状明显,需要药物治疗来缓解、控制症状。西医多采用补充雌激素的方法予以治疗,如利维爱、尼尔雌醇等,属于治标式治疗方法,其临床症状治愈率不够理想,且花费较高。
中医认为更年期综合征是肾阴亏虚,君相火旺,肝血不足,以至阴阳失衡,因此在治疗时,以补肾气、调阴阳为主要方法,属于治本式治疗方法,由于涉及脏器较多,临证当仔细审证求因,分别施治。目前临床上主要是针对更年期综合征的某一事实,采取调整体内内分泌激素的水平或提高脑内单胺类递质的含量治疗更年期综合征,虽短期症状缓解明显,但其产生的副作用也是一个不容忽视的事实。
发明内容
本申请发明人经过深入的研究和创造性的劳动,提供一种治疗效果好、效率高、对人体无毒副作用的治疗更年期综合征的中药制剂处方。
根据中医药理论,经过发明人的不断探索,利用中药独特的药性,对所属领域的中药进行精心筛选,得到了一种治疗更年期综合征的中药配方,配方为:当归、郁金、佩兰、蝉蜕、黄芪、甘草、连翘、炮附片、刺五加、委陵菜、泽兰、青风藤、一枝黄花、洪连、草豆蔻、秦皮、狗脊、蒲公英、乌梅、桑葚、浮小麦、松花粉、蒺藜苗、败酱草、红背马蓝。
制备本发明中药制剂由下述原料药制成,以重量比计算:当归15-25份、郁金10-18份、佩兰3-9份、蝉蜕2-8份、黄芪10-16份、甘草8-14份、连翘5-10份、炮附片0.2-1份、刺五加1-5份、委陵菜3-7份、泽兰3-7份、青风藤2-5份、一枝黄花1-3份、洪连6-11份、草豆蔻2-7份、秦皮3-7份、狗脊9-17份、蒲公英10-25份、乌梅6-12份、桑葚3-9份、浮小麦6-14份、松花粉3-10份、蒺藜苗4-10份、败酱草5-11份、红背马蓝5-9份。
对上述的中药制剂进行优选,优选的重量份为:当归20份、郁金14份、佩兰6份、蝉蜕5份、黄芪13份、甘草11份、连翘7.5份、炮附片0.5份、刺五加3份、委陵菜5份、泽兰5份、青风藤3.5份、一枝黄花2份、洪连8.5份、草豆蔻4.5份、秦皮5份、狗脊13份、蒲公英17份、乌梅9份、桑葚6份、浮小麦10份、松花粉6.5份、蒺藜苗7份、败酱草8份、红背马蓝7份。或者:当归21份、郁金14.5份、佩兰6份、蝉蜕5份、黄芪12份、甘草9份、连翘6.5份、炮附片0.5份、刺五加3份、委陵菜5份、泽兰6份、青风藤3.5份、一枝黄花2份、洪连8.5份、草豆蔻4.5份、秦皮5份、狗脊13份、蒲公英17份、乌梅9份、桑葚7份、浮小麦10份、松花粉6.5份、蒺藜苗8.5份、败酱草8份、红背马蓝8份。
根据中医药理论,本发明中药制剂处方中使用的中药的药理作用如下:
当归:味甘,性温。
归经:归肝、心、脾经。
功能主治:补血活血,调经止痛,润肠通便。用于血虚萎黄,眩晕心悸,月经不调,经闭痛经,虚寒腹痛,肠燥便秘,风湿痹痛,跌扑损伤,痈疽疮疡。酒当归活血通经。用于经闭痛经,风湿痹痛,跌扑损伤。
郁金:味辛,性寒。
归经:归肝、心、肺经。
功能主治:行气化瘀,清心解郁,利胆退黄。用于经闭痛经,胸腹胀痛、刺痛,热病神昏,癫痫发狂,黄疸尿赤。
佩兰:味辛,性平。
归经:归脾、胃、肺经。
功能主治:芳香化湿,醒脾开胃,发表解暑。用于湿浊中阻,脘痞呕恶,口中甜腻,口臭,多涎,暑湿表症,头胀胸闷。
蝉蜕:味甘,性寒。
归经:归肺、肝经。
功能主治:散风除热,利咽,透疹,退翳,解痉,用于风热感冒,咽痛,音哑,麻疹不透,风疹瘙痒,目赤翳障,惊风抽搐,破伤风。
黄芪:味甘,性温。
归经:入肺、脾经。
功能主治:补气升阳,固表受汗,托疮生肌,利水消肿。
甘草:味甘,性平。
归经:入脾、胃、心、肺经。
功能主治:补中益气,清热解毒,祛痰止咳,缓急止痛。
连翘:味苦,性寒。
归经:归肺、心、小肠经。
功能主治:清热解毒,消肿散结。用于痈疽,瘰疠,乳痈,丹毒,风热感冒,温病初起,温热入营,高热烦渴,神昏发斑,热淋尿闭。
炮附片:味辛、甘,性热,有毒。
归经:归心、肾、脾经。
功能主治:回阳救逆,补火助阳,散寒止痛。用于亡阳虚脱,肢冷脉微,心阳不足,胸痹心痛,虚寒吐泻,脘腹冷痛,肾阳虚衰,阳痿宫冷,阴寒水肿,阳虚外感,寒湿痹痛。
刺五加:味苦,性温。
归经:归脾、肾、心经。
功效:益气健脾,补肾安神,脾肾阳虚,腰膝酸痛。
临床应用:常用于风湿痹痛,腰膝酸痛,该品能调整脏腑气血功能,改善血液循环,促进新陈代谢,使皮肤得到足够的气血运行和正常营养。
委陵菜:味苦,微寒。
功能主治:清热解毒,散瘀止血。治骨结核,口腔炎,瘰疬,跌打损伤,外伤出血。
泽兰:味苦,性温。
归经:归肝、脾经。
功能主治:活血化瘀,行水消肿。用于月经不调,经闭,痛经,产后瘀血腹痛,水肿。
青风藤:味苦,性温。
归经:归肝、脾经
功能:祛风湿,通经络,利小便。主治用于风湿痹痛,关节肿胀,麻痹瘙痒。
一枝黄花:味辛,性平,有小毒。
功能主治:疏风清热,解毒消肿。用于上呼吸道感染,扁桃体炎,咽喉肿痛,支气管炎,肺炎,肺结核咳血,急、慢性肾炎,小儿疳积;外用治跌打损伤,毒蛇咬伤,疮疡肿毒,乳腺炎。
蒺藜苗:味辛;性平。
归经:肝经
功能主治:祛风;除湿;止痒;消痈。主暑湿伤中;呕吐泄泻;鼻塞流涕;皮肤风痒;疥癣;痈肿
败酱草:味辛、苦,凉。
归经:入胃、大肠、肝经。
功能主治:清热解毒,消痈排脓,活血行瘀。用于肠痈、肺痈及疮痈肿毒,实热瘀滞所致的胸腹疼痛,产后瘀滞腹痛等症。
洪连:味苦,性寒。
功能主治:清热解毒,降血压,调经。主急慢性肝炎;肾炎;肺脓疡;高血压;月经常不调;乳腺癌。
益智:味辛,气温。
归经:入肺、脾、肾三经。
功能主治:能补君、相二火,和中焦胃气,逐寒邪,禁遗精溺,止呕哕,摄涎唾,调诸气,以安三焦。
草豆蔻:味辛,性温。
归经:归脾、胃经。
功能主治:燥湿健脾,温胃止呕。用于寒湿内阻,脘腹胀满冷痛,嗳气呕逆,不思饮食。
秦皮:味苦,性寒。
归经:归肝、胆、大肠经。
功能主治:清热燥湿,收涩,明目。用于热痢,泄泻,赤白带下,目赤肿痛,目生翳膜。
狗脊:味苦,性温。
归经:归肝、肾经。
功能主治:补肝肾,强腰脊,祛风湿。用于腰膝酸软,下肢无力,风湿痹痛。
蒲公英:味苦,性寒。
归经:归肝、胃经。
功能主治:清热解毒,消肿散结,利尿通淋,用于疔疮肿毒,乳痈瘰疠,目赤咽痛,肺、肠痈,湿热黄疸,热淋涩痛。
乌梅:味酸,性平。
归经:归肝、脾、肺、大肠经。
功能主治:敛肺,涩肠,生津,安蛔。用于肺虚久咳,久痢滑肠,虚热消渴,蛔厥呕吐腹痛,胆道蛔虫症。
浮小麦:味甘,性凉。
功能主治:止虚汗,养心安神。用于体虚多汗,脏躁症。
松花粉:味甘,性温
归经:肝;胃经
功能主治:祛风;益气;收湿;止血。主头痛眩晕;泄泻下痢;湿疹湿疮;创伤出血。
红背马蓝:味苦,性平
功能主治:活血散瘀;清热解毒。主月经不调;产后恶露不尽;湿热痢疾;疔疮痈肿;跌打损伤;骨折
郁金:味辛,性寒。
归经:归肝、心、肺经。
功能主治:行气化瘀,清心解郁,利胆退黄。用于经闭痛经,胸腹胀痛、刺痛,热病神昏,癫痫发狂,黄疸尿赤。
桑葚:味甘,性寒。
归经:归心、肝、肾经。
功能主治:补血滋阴,生津润燥。用于眩晕耳鸣,心悸失眠,须发早白,津伤口渴,内热消渴,血虚便秘。
发明人还提供了一种用于治疗更年期综合征制备方法:
(1)取当归、郁金、佩兰、蝉蜕、黄芪、委陵菜、泽兰、青风藤、蒲公英、乌梅、桑葚、浮小麦和败酱草加水浸泡1.5小时,武火烧开10min,文火1.5小时,煎煮两次,减压浓缩至90℃,密度为1.10的浸膏,备用;
(2)取甘草、连翘、炮附片、刺五加和一枝黄花研磨成粗粉加70%乙醇提取2次,每次2小时,合并药液,静置24小时,备用;
(3)取洪连、草豆蔻、秦皮、狗脊、松花粉、蒺藜苗和红背马蓝粉碎成细粉用适量70%乙醇提取2次,每次1.5小时,收集提取液,合并药液,静置24小时,备用;
(4)取第(2)和(3)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.03的浸膏,备用;
(5)将步骤(1)和(4)的浸膏混合均匀得到混合物,与药学上可接受的辅料制备成药物制剂。
上述制备方法中的药物制剂,所述药物制剂步骤(5)所述的药物剂型选自颗粒剂、胶囊剂、片剂、注射剂、酊剂、栓剂、丸剂、糖浆剂、合剂、散剂、洗剂、膜剂、滴丸中的一种。其中胶囊剂的制备为加入步骤(5)混合物重量10%的乳糖和糊精的混合物,乳糖和糊精的混合物中乳糖和和糊精的重量比为1:1;搅拌均匀加热至75℃,干燥,加入粘合剂过16目筛,制粒,干燥并装入胶囊,即得胶囊剂;颗粒剂的辅料可为蔗糖粉、羟甲基纤维素钠、糊精及矫味剂等中进行选择;散剂可从淀粉、白陶土、磷酸钙、沉降碳酸钙等中选择;丸剂的辅料可从淀粉、微晶纤维素、预胶化淀粉等中进行选择;片剂的辅料可从淀粉、糊精、微晶纤维素、预胶化淀粉、硬脂酸镁、乳糖、糖粉、羧甲淀粉钠等中进行选择。
如上所述的制备方法所述的药物制剂在制备治疗更年期综合征、妇女围绝经期综合症及预防更年期综合征药物中的用途。尤其是制备治疗更年期综合征抑郁证药物中的用途。
本发明所述的药物制剂用于,与现有技术相比具有如下优势:
本发明选用的中药材,注重阴阳协调,利用各味药的综合作用治疗更年期综合征,经过毒性试验可以说明本发明的安全性较高,适合进一步推广应用。从中药材中提取的蛋白质等物质,容易被人体利用,达到解郁散结、安神定气具有良好的作用。另外,本发明的胶囊剂操作简单适合工艺化大生产。
具体实施例
对于本领域技术人员而言,显然本发明实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。均应将实施例看作是示范性的,而且是非限制性的,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
实施例1:一种用于治疗更年期综合征抑郁证的胶囊剂,含有以下重量份中药材:
当归15克、郁金10克、佩兰3克、蝉蜕2克、黄芪10克、甘草8克、连翘5克、炮附片0.2克、刺五加1克、委陵菜3克、泽兰3克、青风藤2克、一枝黄花1克、洪连6克、草豆蔻2克、秦皮3克、狗脊9克、蒲公英10克、乌梅6克、桑葚3克、浮小麦6克、松花粉3克、蒺藜苗4克、败酱草5克、红背马蓝5克。
制备方法为:
(1)取当归、郁金、佩兰、蝉蜕、黄芪、委陵菜、泽兰、青风藤、蒲公英、乌梅、桑葚、浮小麦和败酱草加水浸泡1.5小时,武火烧开10min,文火1.5小时,煎煮两次,减压浓缩至90℃,密度为1.10的浸膏,备用;
(2)取甘草、连翘、炮附片、刺五加和一枝黄花研磨成粗粉加70%乙醇提取2次,每次2小时,合并药液,静置24小时,备用;
(3)取洪连、草豆蔻、秦皮、狗脊、松花粉、蒺藜苗和红背马蓝粉碎成细粉用适量70%乙醇提取2次,每次1.5小时,收集提取液,合并药液,静置24小时,备用;
(4)取第(2)和(3)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.03的浸膏,备用;
(5)将步骤(1)和(4)的浸膏混合均匀,与药学上可接受的辅料制备成药物制剂(加入混合物重量10%的乳糖和糊精的混合物,乳糖和糊精的混合物中乳糖和和糊精的重量比为1:1)。
实施例2:一种用于治疗更年期综合征抑郁证的胶囊剂,含有以下重量份中药材:
当归25克、郁金18克、佩兰9克、蝉蜕8克、黄芪16克、甘草14克、连翘10克、炮附片1克、刺五加5克、委陵菜7克、泽兰7克、青风藤5克、一枝黄花3克、洪连11克、草豆蔻7克、秦皮7克、狗脊17克、蒲公英25克、乌梅12克、桑葚9克、浮小麦14克、松花粉10克、蒺藜苗10克、败酱草11克、红背马蓝9克。
制备方法同实施例1。
实施例3:一种用于治疗更年期综合征抑郁证的胶囊剂,含有以下重量份中药材:
当归20克、郁金14克、佩兰6克、蝉蜕5克、黄芪13克、甘草11克、连翘7.5克、炮附片0.5克、刺五加3克、委陵菜5克、泽兰5克、青风藤3.5克、一枝黄花2克、洪连8.5克、草豆蔻4.5克、秦皮5克、狗脊13克、蒲公英17克、乌梅9克、桑葚6克、浮小麦10克、松花粉6.5克、蒺藜苗7克、败酱草8克、红背马蓝7克。
制备方法同实施例1。
实施例4:一种用于治疗更年期综合征抑郁证的胶囊剂,含有以下重量份中药材:
当归21克、郁金14.5克、佩兰6克、蝉蜕5克、黄芪12克、甘草9克、连翘6.5克、炮附片0.5克、刺五加3克、委陵菜5克、泽兰6克、青风藤3.5克、一枝黄花2克、洪连8.5克、草豆蔻4.5克、秦皮5克、狗脊13克、蒲公英17克、乌梅9克、桑葚7克、浮小麦10克、松花粉6.5克、蒺藜苗8.5克、败酱草8克、红背马蓝8克。
制备方法同实施例1。
实施例5:更年期综合征抑郁证动物模型
5.1、动物建模
SD生育龄未孕雌性大鼠,清洁级,体质量180~220g;将动物双侧卵巢摘除后,单笼饲养,每天接受一种不同的刺激,刺激项目分别为冰水游泳,电击足底,热应激,夹尾,摇晃,昼夜颠倒和禁水,禁食。连续7天若动物对开始刺激产生应激,则表明造模成功。
5.2、分组以及给药
造模结束后大鼠随机分成5组:模型组、安定片组(5mg/kg)、胶囊剂高剂量组(6g/kg)、胶囊剂中剂量组(3g/kg)、胶囊剂低剂量组(1.5g/kg),每组10只,另取体重所述的胶囊剂按照本发明实施例3制备得到。结果见表1.
5.3、饮食变化
发明人为了进一步刺激大鼠的饮水欲,在水中加入适量的蔗糖,配制成1.1%的蔗糖水,以其满足试验要求。实验前禁止喝水24h,与试验之后第1、4周时观测各组大鼠1h内的饮用蔗糖水量,结果如下表2。
表2不同组别大鼠的饮用蔗糖水的情况
组别 | 1周(mL) | 4周(mL) |
正常对照组 | 16.23±6.27 | 17.11±5.79 |
模型组 | 10.11±6.39## | 6.01±4.17## |
胶囊剂高剂量组 | 10.21±5.23## | 16.92±6.16**¥ |
胶囊剂中剂量组 | 10.20±6.01## | 15.83±5.23** |
胶囊剂低剂量组 | 10.13±5.88## | 14.55±4.88** |
安定片组 | 10.11±4.27## | 14.29±4.73** |
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,*P<0.05,**P<0.01;
与安定片组比较,¥P<0.05。
从表2可以看出,经过23天造模,模型组大鼠24h饮用蔗糖水均明显低于正常对照组(##P<0.01),表明造模成功;在第4周时,安定片组及胶囊剂低、中、高三剂量组的饮用蔗糖水均明显高于模型对照组(**P<0.01或者*P<0.05),并且胶囊剂高剂量组各组明显高于安定片组(¥P<0.05),二者均具有统计学差异。因此,本发明的中药处方的治疗效果明显优于安定片。
5.4、各组大鼠站立次数的变化
在第2周中午9:00-10:00内分别观察各组大鼠的活动次数、站立次数变化情况。
表3不同组别大鼠的体重的情况
注:
与正常对照组比较,##P<0.01;
与模型对照组比较,*P<0.05,**P<0.01;
与安定片组比较,¥P<0.05。
从表3可以看出,经过23天造模,模型组大鼠体重明显低于正常对照组(##P<0.01),表明造模成功,安定片组及胶囊剂低、中、高三剂量组的体重明显高于模型对照组(**P<0.01或者*P<0.05),并且在第4周时,胶囊剂高剂量组各组明显高于安定片组(¥P<0.05),二者具有统计学差异。
实施例6:动物模型试验和体外实验
将实施例1、2、4制备的胶囊剂替代实施例6中使用的实施例3的胶囊剂,重复实施例6,结果发现实施例1、2、4制备的胶囊剂在和实施例3同等效力。
实施例7:临床资料
7.1、一般资料:
本发明的中药制剂应用于临床观察的病例195例,均为女性,年龄40-55岁,平均年龄为47.5岁。随机分为2组,分别为治疗组和观察组,两组年龄、性别、患病情况均无明显差异(P>0.05)。
7.2、诊断标准及疗效标准:
7.2.1诊断标准
依据卫生部颁发的《中药新药治疗女性更年期综合征临床研究指导原则》。临床表现为:月经紊乱,潮热面红,烘热汗出,烦躁易怒,心悸失眠,胸闷头加,情志异常,记忆力减退等。
7.2.2疗效判定标准
参照《中药新药治疗女性更年期综合征临床研究指导原则》中的疗效判定标准进行制定。
显效:临床症状减少90%以上,理化检查结果恢复至相应水平,且持续6个月以上无反复;
有效:临床症状减少30-90%,理化检查结果有所改善,且6个月内无反复;
无效:临床症状减少30%以下,理化指标无好转或恶化。
7.3、给药方案
治疗组:服用本发明实施例3制备的胶囊剂,口服,每日3次,每次4粒;30天为一疗程,观察3个疗程。
观察组:服用坤泰胶囊,口服,每日3次,每次4粒;30天为一疗程,观察3个疗程。
表4临床治疗组合观察组情况
显效 | 有效 | 无效 | 有效率(%) | |
治疗组 | 88 | 9 | 0 | 100 |
观察组 | 50 | 31 | 16 | 83.5 |
7.4、临床治疗结果
经过2个疗程的观察,结果表明,治疗组显效88例,有效9例,无效0例,有效率100%,对照组50例,有效31例,无效16例,有效率83.5%。表明本发明的胶囊剂疗效确切。
7.5、典型病例:
病例1:薛某,女,43岁,山东郯城人,2014年2月开始出现月经不调,并伴有烘热汗出,烦躁易怒,心悸失眠,胸闷头加等症状,经市医院鉴定患上了抑郁症,服用本发明实施例3的胶囊剂采用本发明实施例3制备的胶囊剂,1个疗程后,症状明显好转,心情开朗,情绪稳定,继续服用2个疗程后,治愈,随访1年,未见复发。
病例2:宋某,女,50岁,辽宁大连人,2015年1月,股市大亏加上创业失败,心情一落千丈,整日郁郁寡欢,对生活没有信心,对自己的孩子漠不关心,经诊断,换上了更年期抑郁症,家人劝其西药治疗均遭到拒绝,安定片服用过但是没有顺序服用,经本院医生劝说服用本发明的实施例4的胶囊剂,心情大为好转,服用3个疗程之后痊愈。3个月电话随访没有复发,患者表示对生活充满信心。
实施例8:毒性验证
8.1、急性毒性试验
受试中药制剂:本发明实施例1-4所制造的胶囊剂,按1:2加纯化水,制成溶液,备用。试验动物:普通级昆明小鼠,体重20g±5g,雌雄各半,雌性小鼠均无孕。
小鼠灌胃本发明中药胶囊剂配制的溶液,当灌胃剂量达到735.5g生药/kg剂量时,给药后小鼠出现轻微活动减少,1小时左右恢复正常,给药后连续观察7天,无一动物死亡,其全身状况、饮食、摄水、小便和体重增长均正常。
试验结果表明:小鼠灌胃实施例1-4所制造的胶囊剂的最大给药量为735.5g生药/kg/d(LD50>735.5g生药/kg)。本发明的中药粉每日临床用药总量最大为0.15g生药/kg/d;按体重计,小鼠灌胃胶囊剂的耐受量为临床病人的4903.3倍。提示该药急性毒性极低,临床用药安全。
8.2、动物长期毒性试验
受试中药制剂:本发明实施例1-4所得中药胶囊剂,按1:2加纯化水,制成溶液,备用。试验动物:普通级SD大鼠,体重210g±14g,雌雄各半,雌性大鼠均无孕。
8.3、方法与结果:
4种中药胶囊剂:均分为高、中、低三个剂量组,单位体重给药量分别为患者服用量的180、60、20倍;将实验鼠随机分成13组,其中12组分别灌胃3种三个剂量的胶囊剂溶液,剩余1组灌胃生理盐水(患者服用量的40倍);所有13组均连续灌胃180天,观察动物全身毒性反应及严重程度,处死后按操作规程检查各部位,并进行血液学,ALT、BUN及心、肝、脾、肺、肾、胃等主要脏器的病理学检查;经过长期喂食,13组大鼠均未出现毒性反应。发育良好。肉眼外观及主要脏器未见异常。外周血象及血清ALT、BUN与对照组比较无病理性改变。病理报告心、肝、脾、肺、肾、胃等均未有意义的改变,因此,认为经病理证实,3种中药胶囊剂对动物无慢性毒性表现。
通过以上两个毒性实验,证明本发明按实施例1-4制作的中药胶囊剂是安全的,无毒副作用的,可以被患者服用。
Claims (9)
1.一种用于治疗更年期抑郁症综合征的药物制剂,其特征在于,所述的药物制剂包括以下中药材:当归、郁金、佩兰、蝉蜕、黄芪、甘草、连翘、炮附片、刺五加、委陵菜、泽兰、青风藤、一枝黄花、洪连、草豆蔻、秦皮、狗脊、蒲公英、乌梅、桑葚、浮小麦、松花粉、蒺藜苗、败酱草、红背马蓝。
2.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:当归15-25份、郁金10-18份、佩兰3-9份、蝉蜕2-8份、黄芪10-16份、甘草8-14份、连翘5-10份、炮附片0.2-1份、刺五加1-5份、委陵菜3-7份、泽兰3-7份、青风藤2-5份、一枝黄花1-3份、洪连6-11份、草豆蔻2-7份、秦皮3-7份、狗脊9-17份、蒲公英10-25份、乌梅6-12份、桑葚3-9份、浮小麦6-14份、松花粉3-10份、蒺藜苗4-10份、败酱草5-11份、红背马蓝5-9份。
3.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:当归20份、郁金14份、佩兰6份、蝉蜕5份、黄芪13份、甘草11份、连翘7.5份、炮附片0.5份、刺五加3份、委陵菜5份、泽兰5份、青风藤3.5份、一枝黄花2份、洪连8.5份、草豆蔻4.5份、秦皮5份、狗脊13份、蒲公英17份、乌梅9份、桑葚6份、浮小麦10份、松花粉6.5份、蒺藜苗7份、败酱草8份、红背马蓝7份。
4.根据权利要求1所述的药物制剂,其特征在于,所述的药物制剂包括以下重量份中药材:当归21份、郁金14.5份、佩兰6份、蝉蜕5份、黄芪12份、甘草9份、连翘6.5份、炮附片0.5份、刺五加3份、委陵菜5份、泽兰6份、青风藤3.5份、一枝黄花2份、洪连8.5份、草豆蔻4.5份、秦皮5份、狗脊13份、蒲公英17份、乌梅9份、桑葚7份、浮小麦10份、松花粉6.5份、蒺藜苗8.5份、败酱草8份、红背马蓝8份。
5.一种制备权利要求1-3任一项所述的药物制剂的制备方法,其特征在于,具体的步骤为:
(1)取当归、郁金、佩兰、蝉蜕、黄芪、委陵菜、泽兰、青风藤、蒲公英、乌梅、桑葚、浮小麦和败酱草加水浸泡1.5小时,武火烧开10min,文火1.5小时,煎煮两次,减压浓缩至90℃,密度为1.10的浸膏,备用;
(2)取甘草、连翘、炮附片、刺五加和一枝黄花研磨成粗粉加70%乙醇提取2次,每次2小时,合并药液,静置24小时,备用;
(3)取洪连、草豆蔻、秦皮、狗脊、松花粉、蒺藜苗和红背马蓝粉碎成细粉用适量70%乙醇提取2次,每次1.5小时,收集提取液,合并药液,静置24小时,备用;
(4)取第(2)和(3)步骤中制得的上清液,减压回收乙醇,浓缩至70℃,密度为1.03的浸膏,备用;
(5)将步骤(1)和(4)的浸膏混合均匀得到混合物,与药学上可接受的辅料制备成药物制剂。
6.根据权利要求5所述的药物制剂的制备方法,其特征在于:步骤(5)所述的药物剂型选自颗粒剂、胶囊剂、片剂、注射剂、酊剂、栓剂、丸剂、糖浆剂、合剂、散剂、洗剂、膜剂、滴丸中的一种。
7.根据权利要求6所述的药物制剂的制备方法,其特征在于:所述的药物剂型选自胶囊剂。
8.根据权利要求1所述的药物制剂,其特征在于:所述的药物制剂在制备治疗更年期抑郁症综合征中的用途。
9.根据权利要求1所述的药物制剂,其特征在于:所述的药物制剂在制备治疗女性更年期抑郁症综合征中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610203268.4A CN105688088A (zh) | 2016-04-03 | 2016-04-03 | 一种用于治疗更年期抑郁症综合征的药物制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610203268.4A CN105688088A (zh) | 2016-04-03 | 2016-04-03 | 一种用于治疗更年期抑郁症综合征的药物制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105688088A true CN105688088A (zh) | 2016-06-22 |
Family
ID=56219023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610203268.4A Pending CN105688088A (zh) | 2016-04-03 | 2016-04-03 | 一种用于治疗更年期抑郁症综合征的药物制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105688088A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115624604A (zh) * | 2022-09-07 | 2023-01-20 | 北京市鼓楼中医医院 | 一种治疗更年期综合征并抑郁的中药组合物及其制备方法与应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319417A (zh) * | 2001-01-18 | 2001-10-31 | 邓虹珠 | 治疗更年期综合症的药物及其制造方法 |
CN1557373A (zh) * | 2004-01-18 | 2004-12-29 | 刘英慧 | 治疗肝郁气滞型更年期综合症的中药制剂及制备方法 |
CN1644209A (zh) * | 2004-11-01 | 2005-07-27 | 辽宁大生药业有限公司 | 一种用于治疗妇女更年期综合症的软胶囊及其制备工艺 |
CN101199771A (zh) * | 2007-12-21 | 2008-06-18 | 北京中科雍和医药技术有限公司 | 一种治疗更年期综合征的药物组合物及其制备方法 |
CN103356899A (zh) * | 2013-07-08 | 2013-10-23 | 贵州宜民中医骨伤烧伤专科医院有限责任公司 | 治疗更年期综合征的药物及其制备方法 |
CN103479783A (zh) * | 2013-09-04 | 2014-01-01 | 上海中医药大学附属岳阳中西医结合医院 | 一种治疗更年期抑郁症的中药组合物及其应用 |
CN104189442A (zh) * | 2014-09-25 | 2014-12-10 | 崔银方 | 一种治疗妇女更年期综合征的中药组合物 |
CN104645246A (zh) * | 2015-03-15 | 2015-05-27 | 陈明友 | 一种用于女性更年期抑郁的药物制剂 |
CN105126045A (zh) * | 2014-05-30 | 2015-12-09 | 曹红霞 | 一种治疗更年期综合征的中药组合物 |
CN105147999A (zh) * | 2015-09-25 | 2015-12-16 | 南京晶云化工有限公司 | 一种用于治疗更年期综合症的药物制剂 |
-
2016
- 2016-04-03 CN CN201610203268.4A patent/CN105688088A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319417A (zh) * | 2001-01-18 | 2001-10-31 | 邓虹珠 | 治疗更年期综合症的药物及其制造方法 |
CN1557373A (zh) * | 2004-01-18 | 2004-12-29 | 刘英慧 | 治疗肝郁气滞型更年期综合症的中药制剂及制备方法 |
CN1644209A (zh) * | 2004-11-01 | 2005-07-27 | 辽宁大生药业有限公司 | 一种用于治疗妇女更年期综合症的软胶囊及其制备工艺 |
CN101199771A (zh) * | 2007-12-21 | 2008-06-18 | 北京中科雍和医药技术有限公司 | 一种治疗更年期综合征的药物组合物及其制备方法 |
CN103356899A (zh) * | 2013-07-08 | 2013-10-23 | 贵州宜民中医骨伤烧伤专科医院有限责任公司 | 治疗更年期综合征的药物及其制备方法 |
CN103479783A (zh) * | 2013-09-04 | 2014-01-01 | 上海中医药大学附属岳阳中西医结合医院 | 一种治疗更年期抑郁症的中药组合物及其应用 |
CN105126045A (zh) * | 2014-05-30 | 2015-12-09 | 曹红霞 | 一种治疗更年期综合征的中药组合物 |
CN104189442A (zh) * | 2014-09-25 | 2014-12-10 | 崔银方 | 一种治疗妇女更年期综合征的中药组合物 |
CN104645246A (zh) * | 2015-03-15 | 2015-05-27 | 陈明友 | 一种用于女性更年期抑郁的药物制剂 |
CN105147999A (zh) * | 2015-09-25 | 2015-12-16 | 南京晶云化工有限公司 | 一种用于治疗更年期综合症的药物制剂 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115624604A (zh) * | 2022-09-07 | 2023-01-20 | 北京市鼓楼中医医院 | 一种治疗更年期综合征并抑郁的中药组合物及其制备方法与应用 |
CN115624604B (zh) * | 2022-09-07 | 2023-10-24 | 北京市鼓楼中医医院 | 一种治疗更年期抑郁症的中药组合物及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN102580000A (zh) | 一种治疗癌性疼痛药物及其制备方法 | |
CN103638451A (zh) | 一种治疗慢性肝炎的中药及其制备方法 | |
CN102526498A (zh) | 治疗鼻咽癌放疗后毒副作用的中药、制备方法及给药方式 | |
CN104225215A (zh) | 一种治疗失眠的中药 | |
CN104353028A (zh) | 一种治疗哮喘的药物组合物及其制备方法 | |
CN101618201B (zh) | 一种治疗外阴粘膜白斑的药物 | |
CN106266999A (zh) | 一种治疗心神不安及心悸失眠的中药组合物及其制备方法 | |
CN102416144A (zh) | 治疗小儿惊风的中药 | |
CN103393825A (zh) | 一种治疗紧张型头痛的中药及其制备方法 | |
CN105688088A (zh) | 一种用于治疗更年期抑郁症综合征的药物制剂 | |
CN102836276B (zh) | 治疗骨性关节炎的骨刺软化丸 | |
CN103157062A (zh) | 一种治疗子宫肌瘤等妇科包块性疾病的药物组合物及其制备方法与应用 | |
CN100473401C (zh) | 一种预防和治疗脑血栓及后遗症的中药制剂 | |
CN105770691A (zh) | 一种用于治疗宫颈癌的药物制剂及其用途 | |
CN104940696A (zh) | 一种治疗肝经湿热型小儿遗尿的药物及其制备方法 | |
CN104398789A (zh) | 一种治疗缺铁性贫血的中药汤剂 | |
CN104013815A (zh) | 一种治疗阴虚火旺型复发性口腔溃疡的中药及制备方法 | |
CN103127398B (zh) | 一种治疗癌症的中药及其制备方法 | |
CN102671000A (zh) | 一种内服治疗高血压的中成药 | |
CN101095922A (zh) | 一种治疗糖尿病性末梢神经炎的中药组合物 | |
CN105832823A (zh) | 一种用于治疗原发性肝癌的药物制剂及其用途 | |
CN105521370A (zh) | 一种用于治疗结肠癌的药物制剂及其用途 | |
CN104524149A (zh) | 一种防治急性肾炎的药物组合物及其应用 | |
CN104524460A (zh) | 一种防治急性肾炎的药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |
|
RJ01 | Rejection of invention patent application after publication |